leadf
logo-loader
viewMaxCyte Inc

MaxCyte - Pole Position in Cell and Gene Therapy

MaxCyte Inc (LON:MXCT) is well-positioned to leverage its proprietary flow electroporation technology that is driving innovation, not only for its differentiated cell therapy platform CARMA but for a fast-growing list of leading industry partners. MXCT has more than 80 licensed programmes including more than 45 licensed for clinical use and has announced seven clinical/commercial partnership deals with front runners in the field of cell and gene therapy. The field is experiencing a huge step up in investment , rising by more than 77% year-on-year in 2018 because of increasing recognition of the potential to offer real hope to sufferers of often advanced and previously untreatable diseases by addressing the root causes, including targeting curative treatments.

 

 

Quick facts: MaxCyte Inc

Price: 410 GBX

AIM:MXCT
Market: AIM
Market Cap: £316.36 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

MaxCyte report 'extraordinary first half' with revenue 30% higher than same...

Maxcyte Inc's (LON:MXCT) Doug Doerfler talks to Proactive London about their full-year revenues which are on track to be 'slightly above' current market expectations. Doerfler discusses what he describes as an 'extraordinary first half' with half year revenue 30% higher than the same period...

3 weeks, 5 days ago

40 min read